Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss how the Biden plan to lower prescription drug costs is disappointing and would lead to less access and higher costs for patients with Scripps National News. https://youtu.be/IeokdBjtjqk...
Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes provide insight on how the full approval Pfizer-BioNTech Covid-19 vaccine might increase vaccinations and affect vaccine mandates on Real News with Rick Outzen on WCOA-AM in Pensacola, FL. ...
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value drugs with Scripps National News. The report aired on 60 television stations in 42 markets across the country reaching 31% of U.S. TV households. https://youtu.be/AK1CIGa-w5c...
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click to download “Establishing a Two-Part Drug Pricing System to Promote Value-Based Pricing and Innovation” “Some policymakers assume that only a centralized agency can determine...
The Pioneer Institute and Pacific Research Institute hosted an educational webinar on the importance of protecting treatment access, innovation, and equity as Washington addresses drug pricing reforms on July 19, 2021. Pioneer Institute, PRI, and special guests explored the current policy landscape on treatment value and access and how policy proposals that lean on the Institute for Clinical and Economic Review, or ICER, and similar approaches could impact certain patients. William “Bill” Smith, PhD, Visiting Fellow in Life Sciences, Pioneer...
Dr. Henry Miller, PRI senior fellow in health care studies, joins PRI's "Next Round" podcast with an update on the pandemic, the progress of vaccine distribution, and his perspective on the CDC’s pause on the use of the Johnson & Johnson vaccine. https://youtu.be/sMwlbxAjrNE...
Watch PRI's Dr. Wayne Winegarden discuss the importance of improving competitions for biosimilars to increase access to these high value medications for more patients on two "Bending the Cost Curve" panel discussions hosted by State of Reform. https://youtu.be/oJTD34j-E-Y https://youtu.be/hu8sWIn3u_A...
Listen to PRI's Dr. Wayne Winegarden discuss the importance of increasing health care transparency and his recent Inside Sources op-ed with host Steve Noxon on "Talk of the Town" on WATR Radio in Waterbury, CT. Click here to listen to the interview...
As they approach the end of the Drug Pricing Maze, the Professor and Pete explore reforms to fix a broken system and encourage the use of cheaper biosimilars that can help patients and the health care system save big. They also learn what can be done to make very expensive gene therapies that provide a lot of value for patients more affordable and accessible....
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no reason to believe that these estimates accurately reflect the value of medicines,” said Dr. Wayne Winegarden, the brief’s author. “The documented biases in their value assessments should raise serious concerns that...
Tearing down drug “rebate walls” that increase patient costs and block access to cheaper and often more effective medications would increase competition, lower out-of-pocket costs, and improve health outcomes, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “America’s patients are harmed because they do not benefit from large, fast-growing rebates when purchasing their medicines,” writes the brief’s author, Dr. Wayne Winegarden, director of PRI’s Center...
Check out all of the videos....
Dr. Henry Miller, PRI senior fellow in health care studies and former founding director of the FDA’s Office of Biotechnology, joins PRI's "Next Round" podcast with an update on efforts to develop vaccines and therapeutics to fight Covid-19. He discusses how a transition between two presidential administrations will affect the work of the federal government in fighting Covid-19, whether a national mask mandate is a good idea, whether Governors like Gavin Newsom should initiate state-level reviews of potential vaccines, and...
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and result in more health and economic consequences. Click here to download the brief “Counterfeit drugs expose patients to potentially lethal contaminants, and may also increase public health risks by failing to effectively...
A new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute found that reforms mandating drug rebates benefit patients rather than payers would lower overall health care costs and help patients with expensive out-of-pocket drug costs. Click here to download the brief “Ironically, the current drug concession system is raising patient costs,” write the briefs authors, Wayne Winegarden and Robert Popovian. “Mandating that all drug concessions must benefit the patients purchasing the medicines is a...
If you’ve ever had a medical procedure and received a large bill from your hospital because, unknown to you, one of your doctors was not in your insurance network – that’s the subject of this podcast. On "Next Round," PRI senior fellow Wayne Winegarden discusses his recently released study on “Surprise Medical Billing.” He explains how it happens, why it happens, and the reforms that could prevent it. https://youtu.be/G4BvoVHT4so...
As they approach the end of the Drug Pricing Maze, the Professor and Pete explore reforms to fix a broken system and encourage the use of cheaper biosimilars that can help patients and the health care system save big. They also learn what can be done to make very expensive gene therapies that provide a lot of value for patients more affordable and accessible....
SAN FRANCISCO – California’s surprise medical billing law (Assembly Bill 72) – which imposes price controls on the rates out-of-network physicians can charge at in-network facilities – is hurting patients with lower quality care, reduced access, and higher health care system costs, finds a new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the brief “California’s surprise medical billing law has created unintended consequences that are increasing healthcare costs and...
The Professor and Pete must collect 3 keys to finally escape the drug pricing maze. The first key involves reforms to increase drug affordability for patients who buy their drugs at a pharmacy. The Professor shows Pete that these reforms should ensure that prices are transparent, easy to understand, and help patients benefit from the large discounts that are being paid....